Abzena

Abzena is a fully integrated biopharmaceutical CDMO and CRO specializing in biologics and bioconjugates. The company provides tailored drug design, development, and GMP manufacturing services across the full product lifecycle—from discovery through commercial manufacturing.

Core Capabilities:

• Biologics: Antibody engineering, protein and antibody expression, cell line development, master cell banking, process development and optimization, clinical and commercial manufacturing, quality control and stability testing, analytical method development, and bioassays.
• Bioconjugates & ADCs: Design and synthesis of linker-payloads, ADC manufacturing, antibody-oligonucleotide conjugates (AOCs), radionuclide drug conjugates (RDCs), process track record, process performance qualification (PPQ), and handling of highly potent materials.
• Analytics & Immunogenicity: Surface plasmon resonance (SPR), early-phase bioassays, immunogenicity assays (EpiScreen T-cell epitope mapping, MAPPS, time-course T-cell assays, cytokine screens, custom immunology assays), and ITOPE/TCED.
• Integrated Programs: HIT-to-lead, IND/BLA, DNA-IND-CTA, and developability assessment.
• Proprietary Solutions: AbzelectPro, Labzient, ThioBridge, and composite protein/antibody platforms.

Abzena deploys best-in-class biologic development technologies, shortens lead times, and implements risk mitigation strategies to accelerate time-to-clinic and commercial launch.